CFON-026

• Description:

  CFON-026 is a selective, orally active and non-covalent BTK inhibitor with an IC50 of 0.27 nM. CFON-026 has significant antitumor activity against wild-type BTK (TMD8 and REC-1) and all clinically relevant BTK resistance mutations (BTK C481S, T474I, L528W and V416L) . CFON-026 induces complete tumor regression in TMD8 xenograft mice model. CFON-026 can be used for research of hematological cancers like chronic lymphocytic leukemia and waldenström macroglobulinemia[1].

• UNSPSC:

  12352005

• Target:

  Btk

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Field of Research:

  Cancer

• Smiles:

  NC1=NC=C2/C=C/CCCCCC(N[C@@H]3CCC[C@@H](C4=NC(C5=CC=C(C(NC6=CC(C#N)=CC=N6)=O)C=C5)=C1N24)C3)=O

• Molecular Formula:

  C33H34N8O2

• Molecular Weight:

  574.68

• References & Citations:

  [1]Mil Y V, et al.151 (PB139) : CFON-026, a best-in-class macrocyclic non-covalent inhibitor of BTK (WT) and all clinically relevant BTK resistance mutations[J].European Journal of Cancer, 2024, 211.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2941611-57-8]